BeOne Medicines (ONC) Enterprise Value (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Enterprise Value of -$4.8 billion for Q1 2026, down 90.42% year-over-year from -$50.0 billion in Q1 2025, and down 5.37% quarter-over-quarter from -$4.5 billion in Q4 2025.
BeOne Medicines (ONC) Enterprise Value (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Enterprise Value for 12 consecutive years, with -$4.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 90.42% year-over-year to -$4.8 billion; the TTM figure through Mar 2026 stood at -$4.8 billion (down 90.42% YoY), while the FY2025 annual figure was -$4.5 billion, down 73.08% from the prior year.
- Enterprise Value fell to -$4.8 billion in Q1 2026 per ONC's latest filing, from -$4.5 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$872.2 million in Q3 2022 and bottomed at -$5.7 billion in Q2 2022.
- Historically, Enterprise Value has averaged -$3.3 billion across 5 years, with a median of -$3.2 billion in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 77.73% — and 2023, when it sank 263.95%.
- BeOne Medicines' Enterprise Value stood at -$4.5 billion in 2022, then rose by 30.0% to -$3.2 billion in 2023, then advanced by 17.23% to -$2.6 billion in 2024, then tumbled by 73.08% to -$4.5 billion in 2025, then declined by 5.37% to -$4.8 billion in 2026.
- Business Quant data shows ONC's Enterprise Value at -$4.8 billion in Q1 2026, -$4.5 billion in Q4 2025, and -$4.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.10 Bn |
| Mar 31, 2026 | -4.79 Bn |
| Dec 31, 2025 | -4.55 Bn |
| Sep 30, 2025 | -4.04 Bn |
| Jun 30, 2025 | -2.76 Bn |
| Mar 31, 2025 | -2.52 Bn |
| Dec 31, 2024 | -2.63 Bn |
| Sep 30, 2024 | -2.70 Bn |
| Jun 30, 2024 | -2.59 Bn |
| Mar 31, 2024 | -2.79 Bn |
| Dec 31, 2023 | -3.17 Bn |
| Sep 30, 2023 | -3.17 Bn |
| Jun 30, 2023 | -3.52 Bn |
| Mar 31, 2023 | -3.83 Bn |
| Dec 31, 2022 | -4.53 Bn |
| Sep 30, 2022 | -872.19 Mn |
| Jun 30, 2022 | -5.70 Bn |
| Mar 31, 2022 | -1.90 Bn |
| Dec 31, 2021 | -2.24 Bn |
| Sep 30, 2021 | -3.92 Bn |